Immunohistochemical Profiles of Breast Cancer Patients at MRCCC Siloam Semanggi Hospital in 2018

Gultom, Fajar Lamhot and Nurprilinda, Marliana and Hutami, Ryani Nur Cahyaning (2021) Immunohistochemical Profiles of Breast Cancer Patients at MRCCC Siloam Semanggi Hospital in 2018. International Journal of Health Sciences and Research, 11 (5). pp. 392-400. ISSN 2249 9571

	Text ImmunohistochemicalProfilesofBreastCancerPatients.pdf Download (217kB)
	Text (Reviewer) ReviewerImmunohistochemicalProfilesofBreastCancerPatients.pdf Download (1MB)
	Text (Reviewer (Ibu Marliana)) ReviewerImmunohistochemicalProfilesofBreastCancer.pdf Download (1MB)
	Text (Hasil Cek Turnitin) TurnitinImmunohistochemicalProfilesofBreastCancerPatients.pdf Download (2MB)

Abstract

Immunohistochemistry examination (IHC) is one of the additional tests to diagnose and determine breast cancer subtype. IHC examination is a method to check intracellular protein using a monoclonal and polyclonal antibody to detect the antigen in tissue. IHC examination determined by hormone receptor markers (ER and PR), HER-2/Neu expression, and apoptotic and proliferation markers (Ki-67 and p53) can be used to determine therapy and prognosis. This study aims to determine the hormonal status of breast cancer patient at Siloam Semanggi Hospital in 2018, in the form of age, gender, pathology diagnose, and the result of IHC (ER, PR, HER2, and Ki-67). This study is a retrospective descriptive study using pathological anatomy laboratory results of breast cancer in MRCCC Siloam Semanggi Hospital and 208 patients following inclusion and exclusion criteria. The result obtained is that the age group with the highest frequency is 50-59 years, with 34.1%. The highest frequency by gender is a woman with 99.5%. Carcinoma mammae NST with grade II and III was found in 38.0% of patients. The hormonal receptor with ER and PR positive was found in 51.0% of patients. HER2 expression negative was found in 56.7% of patients. High proliferation Ki-67 was found in 82.7% of patients. Luminal B with HER2 negative subtype was found in 32.2% of patients. Patients in 50-59 years with Luminal B with HER2 negative subtype was found in 26 patients. Patients in carcinoma mammae NST with grade II with Luminal B with HER2 negative subtype was found in 27 patients.

Actions (login required)

View Item